Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333009 | 0.90 | PTPN1 (0.51) | PTPN1PTPN12KDM4EALDH1A1HPGD | |
| SCHEMBL4451545 | 0.89 | PTPN1 (0.50) | PTPN1PTPN12KDM4EALDH1A1HPGD | |
| SCHEMBL4324296 | 0.83 | PTPN1 (0.43) | PTPN1PTPN12KDM4EALDH1A1HPGD | |
| SCHEMBL4336070 | 0.82 | KDM4E (0.47) | KDM4EALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL4336074 | 0.82 | KDM4E (0.47) | KDM4EALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL4329136 | 0.82 | KDM4E (0.56) | KDM4EALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL4329138 | 0.82 | KDM4E (0.56) | KDM4EALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL4341378 | 0.81 | MAPT (0.48) | KDM4EALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL4341232 | 0.79 | KMT2A (0.58) | KDM4EALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL4325235 | 0.77 | ALDH1A1 (0.73) | PTPN1PTPN12KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | PTPN1 476/4885PTPN12 960/4885KDM4E 3010/4885 |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | PTPN1 525/4885PTPN12 825/4885KDM4E 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.